These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30412911)

  • 1. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
    Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
    Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
    Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
    Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
    Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
    Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
    Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
    J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
    Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
    Stafman LL; Waldrop MG; Williams AP; Aye JM; Stewart JE; Mroczek-Musulman E; Yoon KJ; Whelan K; Beierle EA
    J Pediatr Surg; 2019 Jun; 54(6):1206-1213. PubMed ID: 30898394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.
    Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
    J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
    Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
    Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
    Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts.
    Williams AP; Garner EF; Stafman LL; Aye JM; Quinn CH; Marayati R; Stewart JE; Atigadda VR; Mroczek-Musulman E; Moore BP; Beierle EA; Friedman GK
    Transl Oncol; 2019 Oct; 12(10):1364-1374. PubMed ID: 31362265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.
    Park YK; Obiang-Obounou BW; Lee KB; Choi JS; Jang BC
    J Cell Mol Med; 2018 Apr; 22(4):2488-2497. PubMed ID: 29441719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
    Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
    Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
    Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
    Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
    Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
    Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
    Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
    Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
    Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.